UNSPSC 51113203: Diaziquone

This classification denotes an ethylenimine compound with the molecular formula C16H20N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQL5EUP13W, chemically known as 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone but more generally known as diaziquone, which bears US NIH Compound Identifier 42616. European Medicines Agency schedules Diaziquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07070MIG. The term DIAZIQUONE is an International Non-Proprietary Name.

UNSPSC 51113203 Diaziquone is a Commodity code for a specific pharmaceutical active ingredient, though recent state and local procurement activity under this code shows minimal direct solicitation. The Texas Health and Human Services Commission posted a Request for Information (RFI) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, but this RFI functions as exploratory market intelligence gathering rather than a purchase order for diaziquone or any named pharmaceutical product. The RFI solicits information from vendors about their capacity to establish direct contracts between state pharmacy benefit programs and pharmaceutical manufacturers, negotiate net pricing models, and fulfill volume requirements outside traditional pharmacy benefit manager and group purchasing organization channels. The procurement emphasizes vendors' experience with direct contracting for self-insured employers and state agencies and their flexibility with outcomes-based pricing agreements, but does not specify pharmaceutical commodities, dosages, quantities, or budget allocations at the information-gathering stage.

State and local procurement activity under this Commodity code remains sparse. The Texas Health and Human Services Commission represents the primary recent buyer posting under UNSPSC 51113203, with the April 2026 RFI serving as an early-stage vehicle to inform future formal solicitations rather than an immediate purchase commitment. No award values, response counts, or formal evaluation criteria appear in the RFI materials. Geographic activity is limited to Texas, with no comparable recent opportunities identified in other states or jurisdictions. Until the Texas HHS Commission issues a formal RFP or IFB following this information-gathering phase, direct procurement under this code remains uncertain and inactive for business development purposes.